Bausch + Lomb Corporation (BLCO) Year-over-year earnings per share growth for the last twelve months

Bausch + Lomb Corp (BLCO) - corporate logo

The quarterly relative change in EPS demonstrates the impact of high debt leverage and market pressure on the cash flow of Bausch + Lomb Corporation (BLCO). Meanwhile, 211.30 represents the current value of this metric. Stable revenue is driven by customer reliance on consumables, while the brand's impeccable reputation among ophthalmologists ensures business resilience regardless of external perception crises.

bausch.com (BLCO) - Year-over-year earnings per share growth for the last twelve months from 04/28/2023 to 11/18/2026

BLCO (bausch.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Analysis of all company metrics:Bausch Health - BLCO
Finished products of Bausch + Lomb Corporation

Quarterly EPS growth measures the dynamics of net income per share, revealing the pace of business scaling or stagnation. This metric is calculated as the percentage deviation of the current result from the same period last year. By analyzing the quarter-over-quarter EPS growth rate, an investor assesses the sustainability of cash flows. For Bausch + Lomb Corporation (BLCO), this trend reflects the impact of debt load and marketing expenses. A decline in this indicator may signal cost pressure on overall profitability.

Main competitors

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Glaukos Medical (GKOS)|Year-over-year earnings per share growth for the last twelve months apellis.com|Belite Bio (BLTE) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth VRDN (Viridian Corp)|LENZ Corp (LENZ) - Earnings per share growth in annualized terms for the last twelve months|OCS: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months eyepointpharma.com|KOD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aldeyra Therapeutics (ALDX)|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)